Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Ergotamine Cyclizine And Caffeine

Ergotamine, Cyclizine, and Caffeine: A Synergistic Trio for Migraine Relief

Introduction

Migraine remains one of the most common and disabling neurological disorders worldwide. Characterized by intense headaches, often accompanied by nausea, vomiting, and sensitivity to light or sound, migraines affect over 1 billion people globally. While modern therapies like triptans and CGRP inhibitors have gained popularity, some multi-agent formulations continue to be vital in clinical practice. One such formulation is the combination of Ergotamine, Cyclizine, and Caffeine, used particularly in acute migraine attacks where nausea and vomiting are prominent features. This synergistic trio addresses the vascular, neurological, and gastrointestinal symptoms of migraines, offering a comprehensive therapeutic option, especially in resource-limited settings.

Overview of the Components

1. Ergotamine

  • A vasoconstrictive ergot alkaloid that acts on serotonin (5-HT1) receptors.

  • Derived from the Claviceps purpurea fungus.

  • Primarily used for acute treatment of migraine headaches.

2. Cyclizine

  • A first-generation antihistamine with strong antiemetic and anticholinergic properties.

  • Acts on the vestibular system to reduce nausea, vomiting, and vertigo.

  • Commonly used in motion sickness and migraine-induced nausea.

3. Caffeine

  • A methylxanthine stimulant found naturally in coffee, tea, and chocolate.

  • Enhances the absorption and efficacy of ergotamine.

  • Mild vasoconstrictor effects and improves alertness.

Mechanism of Action

Ergotamine

  • Stimulates 5-HT1B and 5-HT1D receptors → constricts intracranial blood vessels.

  • Reduces neurogenic inflammation in the trigeminovascular system.

  • Also stimulates alpha-adrenergic receptors, contributing to vasoconstriction.

Cyclizine

  • Blocks histamine H1 receptors in the vomiting center and vestibular nuclei.

  • Reduces nausea and vomiting by suppressing labyrinthine activity.

  • Has anticholinergic effects, reducing GI motility and sensitivity.

Caffeine

  • Inhibits phosphodiesterase, leading to increased cAMP.

  • Constriction of cerebral blood vessels, countering the vasodilation in migraines.

  • Enhances the bioavailability of ergotamine by improving GI absorption.

Together, these three components address pain, nausea, and inflammation—making the combination especially valuable in patients with migraine with significant gastrointestinal symptoms.

Pharmacokinetics

Component Absorption Peak Effect Half-life Metabolism Excretion
Ergotamine Poor alone, improved with caffeine 1–2 hours 2–4 hours Hepatic (CYP3A4) Fecal
Cyclizine Rapid oral absorption 1–3 hours 20 hours Hepatic Renal
Caffeine Rapid and complete 30–90 minutes 3–7 hours Hepatic (CYP1A2) Renal

Caffeine significantly enhances the absorption of ergotamine, while cyclizine helps mitigate nausea that might otherwise lead to vomiting and reduced drug efficacy.

Clinical Indications

This combination is indicated primarily for:

  • Acute migraine attacks (with or without aura)

  • Migraine associated with severe nausea or vomiting

  • Cases where patients experience motion sensitivity or vertigo as part of migraine

It is not recommended for migraine prevention or chronic daily headaches.

Dosage and Administration

  • Formulation: Tablets typically containing:

    • Ergotamine tartrate 1 mg

    • Cyclizine hydrochloride 50 mg

    • Caffeine 100 mg

  • Usual Adult Dose:

    • 1–2 tablets at the onset of migraine

    • May repeat every 30 minutes as needed

    • Maximum: 6 tablets per attack; no more than 10 tablets per week

  • Route: Oral; sublingual formulations may be used in some regions

Patients should be advised to take medication early in the migraine attack for maximum efficacy.

Clinical Efficacy

Several studies and clinical experiences suggest that this combination:

  • Provides rapid pain relief, often within 1–2 hours

  • Reduces the intensity and duration of attacks

  • Decreases associated nausea and vertigo

  • Is useful in patients who cannot tolerate triptans or newer CGRP agents

The added cyclizine makes this combination particularly effective in patients who experience significant GI upset, enhancing both comfort and compliance.

Adverse Effects

While generally effective, this combination can produce a range of side effects:

Common

  • Drowsiness (from cyclizine)

  • Dry mouth

  • Nausea (paradoxical in some)

  • Restlessness or jitteriness (from caffeine)

  • Dizziness

Serious

  • Ergotism: peripheral vasospasm leading to pain, numbness, or gangrene

  • Cardiac ischemia: due to vasoconstriction

  • Overdose toxicity: tremors, convulsions, or hallucinations

Cyclizine-Specific

  • Blurred vision

  • Urinary retention

  • Confusion (especially in the elderly)

Patients must be educated on signs of toxicity, especially ergot-related ischemic symptoms.

Contraindications

  • Pregnancy (Category X – risk of uterine contraction and fetal harm)

  • Peripheral vascular disease

  • Coronary artery disease or angina

  • Uncontrolled hypertension

  • Severe liver or kidney disease

  • Concurrent use with triptans

  • Use with strong CYP3A4 inhibitors (increased ergotamine toxicity risk)

Drug Interactions

  • Triptans: Avoid within 24 hours due to vasoconstriction risk

  • Macrolide antibiotics (e.g., erythromycin): increase ergotamine toxicity

  • CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): increase ergotamine levels

  • Alcohol and sedatives: amplify CNS depression from cyclizine

  • Beta-blockers: may worsen vasospastic effects

Special Populations

Elderly

  • Greater sensitivity to anticholinergic effects of cyclizine

  • Increased risk of cardiac side effects from ergotamine

Pregnancy and Lactation

  • Contraindicated in pregnancy

  • Not recommended during lactation due to potential adverse effects on the infant

Children

  • Safety and efficacy not established

Patient Counseling Points

  • Take medication at first sign of migraine (not during aura phase)

  • Avoid repeating doses too frequently to prevent overuse headaches

  • Do not combine with triptans or other vasoconstrictors

  • Avoid grapefruit juice (CYP3A4 inhibition)

  • Watch for numbness, cold extremities, chest pain, and report them immediately

  • Avoid alcohol and sedatives due to risk of enhanced drowsiness

Comparison with Other Migraine Therapies

Feature Ergotamine + Cyclizine + Caffeine Triptans NSAIDs
Migraine relief Yes Yes Mild to moderate
Nausea control Yes (via cyclizine) No No
Vasoconstriction risk High Moderate None
Use in pregnancy No No Some (caution)
Sedation risk Yes (cyclizine) Minimal No
Cost Lower Moderate to high Low

Advantages

  • Addresses multiple migraine symptoms: pain, nausea, and vascular changes

  • Affordable, especially in low-resource settings

  • Long duration of action compared to some triptans

  • Available in oral and sublingual forms

Disadvantages

  • More side effects than newer drugs

  • Risk of ergotism if used inappropriately

  • Potential for medication-overuse headaches (MOH)

  • Contraindicated in pregnancy and cardiovascular disease

Regulatory and Market Status

  • This combination is available in many countries, often under generic or branded names.

  • In some regions, its use is limited or replaced by newer options due to safety concerns.

  • Still recommended by clinicians familiar with ergot derivatives, especially for specific patient populations.

Recent Trends and Alternatives

While the migraine treatment landscape has evolved dramatically with the introduction of:

  • CGRP inhibitors (erenumab, fremanezumab)

  • Ditans (lasmiditan)

  • Gepants (ubrogepant, rimegepant)

… the ergotamine-cyclizine-caffeine combo remains clinically relevant, especially:

  • When newer drugs are unavailable

  • In cases of mixed headache syndromes

  • When antiemetic coverage is essential

Conclusion

The combination of ergotamine, cyclizine, and caffeine offers a comprehensive approach to treating acute migraines. Its unique formulation targets vascular pain, nausea, and migraine-associated neurochemical dysfunctions. While not suitable for everyone, it continues to be a viable, affordable, and effective option, especially for patients who experience migraine with nausea and vomiting. Careful patient selection, adherence to dosing guidelines, and monitoring for side effects are essential to maximize benefits and minimize risks.